Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 10:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 387 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Depression in Adults Clear all
Completed Not applicable Interventional Results available

Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD

NCT02634177
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Assay-guided treatment (AGT), Treatment-as-usual (TAU)
Genetic · Other
Lead sponsor
Genomind, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Springdale, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intelligent Personal Assistant for Managing Depression in Homebound Older Adults

NCT04900272
View directory record Official record
Conditions
Aging, Physical Dependence
Interventions
VIPA and companion booklet
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
65 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 13, 2026, 10:36 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

NCT07300969
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
DT-101, Placebo
Drug
Lead sponsor
Draig Therapeutics Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
23
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Oceanside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

NCT03039192
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Esketamine, Placebo, Standard of Care
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
17
States / cities
Birmingham, Alabama • Chandler, Arizona • Garden Grove, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Phase 2 Interventional

ALTO-300 in Depression (ALTO-300-004)

NCT05157945
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ALTO-300 PO Tablet
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 74 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Atlanta, Georgia • Jackson, Mississippi • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Not applicable Interventional

Suicide Prevention Among Recipients of Care

NCT04893447
View directory record Official record
Conditions
Suicide, Suicide, Attempted, Suicidal Ideation, Social Support, Secondary Prevention, Patient Care Planning, Outpatients, Outpatient Clinics, Hospital, Mental Health Services, Mental Health, Mental Disorder, Loneliness, Emergency Service, Hospital, Depressive Disorder, Depression, Continuity of Patient Care, Ambulatory Care, Adolescent, Adult, Crisis Intervention
Interventions
SPI+, SP+CC (Caring Contacts)
Behavioral
Lead sponsor
St. Luke's Health System, Boise, Idaho
Other
Eligibility
12 Years and older
Enrollment
1,520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 13, 2026, 10:36 PM EDT
Recruiting Phase 2 Interventional

Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

NCT07226661
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
SPN-821 2400 mg, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Not applicable Interventional

Adapting BA for Minimally Verbal Autistic Adults

NCT06064422
View directory record Official record
Conditions
Autism, Depression, Autism Spectrum Disorder With Impaired Functional Language, Autism Spectrum Disorder
Interventions
BeatIt-MV
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Phase 4 Interventional Results available

Memantine Treatment for Improving Rehabilitation Outcomes and Preventing Depression in Older Adults

NCT00183729
View directory record Official record
Conditions
Depression
Interventions
Memantine, Placebo
Drug · Other
Lead sponsor
Eric Lenze
Other
Eligibility
60 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder

NCT03672175
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
53
States / cities
Rogers, Arkansas • Bellflower, California • Garden Grove, California + 44 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 13, 2026, 10:36 PM EDT
Withdrawn Phase 2 Interventional

A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone

NCT04965272
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
36
States / cities
Little Rock, Arkansas • Colton, California • Costa Mesa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Sep 13, 2026, 10:36 PM EDT
Terminated Not applicable Interventional

Piano Training, Caregivers, and Parkinson's Disease

NCT03922672
View directory record Official record
Conditions
Depression, Mood, Burden, Dependency
Interventions
Group piano training
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
40 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

A Comparative Study of Sage-217 Plus an Antidepressant (ADT) Versus Placebo Plus an ADT in Adults With Major Depressive Disorder

NCT04476030
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
SAGE-217, Matching Placebo, Sertraline, Escitalopram, Citalopram, Duloxetine, Desvenlafaxine
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 64 Years
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
51
States / cities
Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

NCT05550532
View directory record Official record
Conditions
Depressive Disorder, Major, Anhedonia
Interventions
Aticaprant, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
51
States / cities
Birmingham, Alabama • Lafayette, California • Orange, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Understanding the Efficacy of Mobile Apps as Intervention for Depression in Adults When Deployed as Part of Primary Care.

NCT03500536
View directory record Official record
Conditions
Depression, Anxiety, Primary Health Care
Interventions
IntelliCare
Behavioral
Lead sponsor
Actualize Therapy
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Not applicable Interventional Results available

Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder in Adults

NCT05384041
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Fisher Wallace Cranial Electrotherapy Stimulator (Active Device), Fisher Wallace Cranial Electrotherapy Stimulator (Placebo Device)
Device
Lead sponsor
Fisher Wallace Laboratories
Industry
Eligibility
21 Years to 65 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)

NCT01360645
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions
OPC-34712 + ADT, Placebo + ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
826 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
37
States / cities
Arcadia, California • Beverly Hills, California • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression

NCT05066672
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
NV-5138, matched placebo
Drug
Lead sponsor
Navitor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Phase 4 Interventional Results available

Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults

NCT00696293
View directory record Official record
Conditions
Major Depressive Disorder, Back Pain, Aged
Interventions
Duloxetine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 13, 2026, 10:36 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)

NCT06941844
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, DT120
Other · Drug
Lead sponsor
Definium Therapeutics US, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
22
States / cities
Little Rock, Arkansas • La Jolla, California • Santa Monica, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Sequential Exposure to Nitrogen Dioxide and Ozone in Healthy Adult Human Volunteers.

NCT02133586
View directory record Official record
Conditions
Respiratory Depression
Interventions
Ozone, Nitrogen dioxide
Other
Lead sponsor
Environmental Protection Agency (EPA)
Federal
Eligibility
18 Years to 40 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 16, 2020 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety & Tolerability of OPC-34712 as Adjunctive Therapy in Treatment of Adult Patients With Major Depressive Disorder

NCT01447576
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
ADT, OPC-34712
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,036 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
32
States / cities
Arcadia, California • San Diego, California • Sherman Oaks, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced Sep 13, 2026, 10:36 PM EDT
Not yet recruiting Phase 4 Interventional

Neurocircuitry Mechanisms and Efficacy of Lumateperone as Adjunctive Therapy for Major Depressive Disorder and History of Early Life Abuse

NCT07369115
View directory record Official record
Conditions
Major Depressive Diorder, Early Life Trauma
Interventions
Lumateperone 42 mg, Placebo
Drug · Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
21 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 13, 2026, 10:36 PM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy

NCT02012218
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
ADT, Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
24
States / cities
Garden Grove, California • Temecula, California • Orlando, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2015 · Synced Sep 13, 2026, 10:36 PM EDT